HRTX - Heron Therapeutics, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Heron Therapeutics, Inc.
Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents.
IPO Date: January 23, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $72.96M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.40 | 3.52%
Avg Daily Range (30 D): $0.02 | 5.23%
Avg Daily Range (90 D): $0.03 | 5.55%
Institutional Daily Volume
Avg Daily Volume: 1.33M
Avg Daily Volume (30 D): 2.08M
Avg Daily Volume (90 D): 2.87M
Trade Size
Avg Trade Size (Sh.): 172
Avg Trade Size (Sh.) (30 D): 322
Avg Trade Size (Sh.) (90 D): 356
Institutional Trades
Total Institutional Trades: 3,475
Avg Institutional Trade: $1.58M
Avg Institutional Trade (30 D): $.7M
Avg Institutional Trade (90 D): $.81M
Avg Institutional Trade Volume: .13M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.02M
Avg Closing Trade (30 D): $.7M
Avg Closing Trade (90 D): $.81M
Avg Closing Volume: 183.4K
 
News
Oct 29, 2025 @ 9:58 PM
Heron Therapeutics Announces Appointment of Thomas...
Source: Craig Collard
Oct 29, 2024 @ 8:05 PM
Heron Therapeutics to Report Third Quarter 2024 Fi...
Source: Prnewswire
Sep 17, 2024 @ 10:00 AM
Chemotherapy Induced Nausea and Vomiting Treatment...
Source: Fact.Mr
Jul 2, 2024 @ 12:43 PM
Merck (MRK) Gets Exclusive Rights to Opevesostat F...
Source: Zacks Equity Research
Jul 1, 2024 @ 2:31 PM
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for R...
Source: Zacks Equity Research
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-.18 $-.03 $-.04
Diluted EPS $-.18 $-.03 $-.04
Revenue $151.18M $37.67M $34.71M
Gross Profit $105.94M $26.09M $24.07M
Net Income / Loss $-34.05M $-5.49M $-8.11M
Operating Income / Loss $-10.86M $-2.04M $-4.77M
Cost of Revenue $45.24M $11.57M $10.64M
Net Cash Flow $4.21M $-5.4M $-2.53M
PE Ratio    
Splits
Jan 13, 2014 1:20
May 25, 2007 1:4